Navidea Biopharmaceuticals Company Profile (NYSEMKT:NAVB)

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSEMKT
  • Symbol: NAVB
  • CUSIP: 63937X10
Key Metrics:
  • Previous Close: $0.89
  • 50 Day Moving Average: $0.6654
  • 200 Day Moving Average: $0.8179
  • 52-Week Range: $0.26 - $2.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.78
  • P/E Growth: 0.0000
  • Market Cap: $138.82M
  • Outstanding Shares: 155,383,000
  • Beta: 0.27
Additional Links:
Companies Related to Navidea Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Navidea Biopharmaceuticals (NYSEMKT:NAVB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Show:
DateFirmActionRatingPrice TargetDetails
10/15/2014AegisReiterated RatingHold -> PositiveView Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016        
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.08)$0.90 million$0.75 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Current Year EPS Consensus Estimate: $-0.0800 EPS
Next Year EPS Consensus Estimate: $-0.0300 EPS

Dividends

Dividend History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.00View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.00View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
DateHeadline
streetinsider.com logoNavidea Biopharma (NAVB) Names New CEO - StreetInsider.com (NYSEMKT:NAVB)
www.streetinsider.com - September 26 at 6:21 PM
publicnow.com logoNavidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer (NYSEMKT:NAVB)
www.publicnow.com - September 26 at 6:21 PM
News IconTrading the Biotech News: Clovis Oncology, Inc. (NASDAQ:CLVS), Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) - The Voice Registrar (NYSEMKT:NAVB)
voiceregistrar.com - September 24 at 10:44 AM
News IconKeen Investors Find News on Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 23 at 5:54 PM
News IconTrader's Focus- Navidea Biopharmaceuticals, Inc's (NAVB) - Hot Stocks Point (NYSEMKT:NAVB)
www.hotstockspoint.com - September 23 at 11:00 AM
capitalcube.com logoETF’s with exposure to Navidea Biopharmaceuticals, Inc. : September 23, 2016 (NYSEMKT:NAVB)
www.capitalcube.com - September 23 at 11:00 AM
News IconUnder the Microscope, Zeroing in at Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 22 at 6:01 PM
News IconPenny Stock Investors Keen on Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 22 at 11:06 AM
streetinsider.com logoNavidea Biopharma (NAVB) to Receive $1M in Lymphoseek-Related Milestone Payments - StreetInsider.com (NYSEMKT:NAVB)
www.streetinsider.com - September 22 at 11:06 AM
publicnow.com logoNavidea Achieves $1 Million in Lymphoseek® Commercial Milestones (NYSEMKT:NAVB)
www.publicnow.com - September 22 at 11:06 AM
News IconUnder the Microscope: Getting a Closer Look at Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 19 at 6:19 PM
News IconShares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) & Synchrony Financial (NYSE:SYF) Stocks News ... - Money News (NYSEMKT:NAVB)
www.newsismoney.com - September 19 at 10:49 AM
smarteranalyst.com logoCompany Update (NYSE MKT:NAVB): Navidea Biopharmaceuticals Inc's Lymphoseek(r) Receives Positive Opinion in ... - Smarter Analyst (NYSEMKT:NAVB)
www.smarteranalyst.com - September 17 at 5:55 PM
streetinsider.com logoNavidea Biopharma (NAVB) Receives Positive EMA CHMP Opinion on Lymphoseek for New Kit (NYSEMKT:NAVB)
www.streetinsider.com - September 16 at 6:05 PM
4-traders.com logoNavidea Biopharmaceuticals : Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass Vial (NYSEMKT:NAVB)
www.4-traders.com - September 16 at 9:52 AM
thestreet.com logoNavidea's Lymphoseek® Receives Positive Opinion In Europe For A New Reduced Mass Vial (NYSEMKT:NAVB)
www.thestreet.com - September 16 at 9:52 AM
publicnow.com logoNavidea’s Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass Vial (NYSEMKT:NAVB)
www.publicnow.com - September 16 at 9:52 AM
finance.yahoo.com logo8:39 am Navidea Biopharma announces that the EMA CHMP has granted a positive opinion for a new Lymphoseek 50 microgram kit for radiopharmaceutical preparation (NYSEMKT:NAVB)
finance.yahoo.com - September 16 at 9:52 AM
News IconStock Update, a Closer Look at Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 15 at 6:24 PM
wallstrt24.com logoNews Recap - Alibaba Group Holding, (NYSE:BABA), Navidea Biopharmaceuticals, (NYSEMKT:NAVB), Under Armour ... - Wall Street 24 (NYSEMKT:NAVB)
wallstrt24.com - September 15 at 6:24 PM
News IconShares Gapping Up Before the Open: Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 15 at 9:48 AM
News IconFeatured Stock: Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) - Post Registrar (NYSEMKT:NAVB)
postregistrar.com - September 15 at 9:48 AM
News IconKeen Investors Narrowing Their Focus on Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 14 at 6:27 PM
News IconTrading Focus - Active Stock Review on Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 14 at 6:27 PM
4-traders.com logoNavidea Biopharmaceuticals : to Present at Upcoming Investor Conferences (NYSEMKT:NAVB)
www.4-traders.com - September 14 at 10:37 AM
publicnow.com logoNavidea to Present at Upcoming Investor Conferences (NYSEMKT:NAVB)
www.publicnow.com - September 14 at 10:37 AM
News IconGetting a Closer Look at Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 12 at 6:02 PM
News IconNavidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Pivots, Poised For Turnaround (NYSEMKT:NAVB)
streetregister.com - September 9 at 11:02 AM
News IconBulls and Bear in Analyst's Spotlight- Navidea Biopharmaceuticals ... - Seneca Globe (NYSEMKT:NAVB)
www.senecaglobe.com - September 8 at 6:07 PM
News IconFocusing the Spotlight on Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 8 at 6:07 PM
capitalcube.com logoETF’s with exposure to Navidea Biopharmaceuticals, Inc. : September 8, 2016 (NYSEMKT:NAVB)
www.capitalcube.com - September 8 at 6:07 PM
News IconBiotech Stocks Worth Chasing: Sequenom Inc. (SQNM), Navidea ... - The Independent Republic (NYSEMKT:NAVB)
theindependentrepublic.com - September 8 at 10:10 AM
News IconMarket Focus - Active Stock Recap on Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 8 at 10:10 AM
News IconNarrowing the Lens on Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - September 8 at 10:10 AM
News IconBiotech Stocks Worth a Closer Look: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Mast Therapeutics, Inc ... - The Voice Registrar (NYSEMKT:NAVB)
voiceregistrar.com - September 8 at 10:10 AM
News IconNavidea Biopharmaceuticals (NAVB) Stock: Continuing Up | Can It Hold Onto Gains? (NYSEMKT:NAVB)
cnafinance.com - September 7 at 6:30 PM
businesswire.com logoNavidea Biopharmaceuticals to Hold Investor Update Call ... - Business Wire (press release) (NYSEMKT:NAVB)
www.businesswire.com - September 7 at 9:52 AM
News IconStock Gapping Higher Pre-Bell: Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 7 at 9:52 AM
News IconSession Chatter - Active Stock Review on Shares of Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 7 at 9:52 AM
proactiveinvestors.co.uk logoUS shares hold onto light gains after Sept rate hike risk ebbs (NYSEMKT:NAVB)
www.proactiveinvestors.co.uk - September 6 at 6:27 PM
News IconNavidea Biopharmaceuticals (NAVB) Stock: Skyrocketing on LOI News (NYSEMKT:NAVB)
www.modestmoney.com - September 6 at 6:27 PM
publicnow.com logoNavidea Biopharmaceuticals to Hold Investor Update Call (NYSEMKT:NAVB)
www.publicnow.com - September 6 at 6:27 PM
proactiveinvestors.co.uk logoUS stocks only slightly higher despite positive news from biotechs (NYSEMKT:NAVB)
www.proactiveinvestors.co.uk - September 6 at 11:01 AM
streetinsider.com logoPre-Open Stock Movers 09/06: (NAVB) (CLCD) (CPHD) Higher; (TNXP) (KPTI) (SCOR) Lower (more...) (NYSEMKT:NAVB)
www.streetinsider.com - September 6 at 11:01 AM
marketwatch.com logoNavidea stock jumps 76% after agreeing to $80 million Cardinal Health deal (NYSEMKT:NAVB)
www.marketwatch.com - September 6 at 11:01 AM
News IconThis Is Navidea Biopharmaceuticals Inc. (NYSEMKT: NAVB)'s Vow - Scibility Media (NYSEMKT:NAVB)
scibilitymedia.com - September 3 at 5:40 PM
istreetwire.com logoMomentum Stocks: CenterPoint Energy, Inc. (CNP), Navidea Biopharmaceuticals, Inc (NAVB), Cobalt International ... - iStreetWire (NYSEMKT:NAVB)
istreetwire.com - September 3 at 10:40 AM
News IconStock Gapping Up Pre-Market: Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - September 1 at 6:18 PM
News IconTime To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Navidea Biopharmaceuticals, Inc (NYSEMKT ... - The Voice Registrar (NYSEMKT:NAVB)
voiceregistrar.com - September 1 at 9:31 AM
wallstrt24.com logoInvestor's Watch List - Facebook, (NASDAQ:FB), Navidea Biopharmaceuticals, (NYSEMKT:NAVB), Devon Energy ... - Wall Street 24 (NYSEMKT:NAVB)
wallstrt24.com - September 1 at 9:31 AM

Social


Last Updated on 9/27/2016 by MarketBeat.com Staff